^
BIOMARKER:
FGFR2 amplification
i
Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
Entrez ID:
Related biomarkers:
›
FGFR2 amplification
|
Gastric Cancer
|
FGFR2 amplification
|
Gastric Cancer
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
FGFR2 amplification
|
Breast Cancer
|
FGFR2 amplification
|
Breast Cancer
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
FGFR2 amplification
|
Cholangiocarcinoma
|
FGFR2 amplification
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
FGFR2 amplification
|
Breast Cancer
|
FGFR2 amplification
|
Breast Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR2 amplification
|
Gastric Cancer
|
FGFR2 amplification
|
Gastric Cancer
|
AMG 552 Sensitive: C2 – Inclusion Criteria
|
AMG 552 Sensitive: C2 – Inclusion Criteria
|
FGFR2 amplification
|
GastroEsophageal Cancer
|
FGFR2 amplification
|
GastroEsophageal Cancer
|
ABSK-091 Sensitive: C3 – Early Trials
|
ABSK-091 Sensitive: C3 – Early Trials
|
FGFR2 amplification
|
Gastric Cancer
|
FGFR2 amplification
|
Gastric Cancer
|
Debio 1347 Resistant: C3 – Early Trials
|
Debio 1347 Resistant: C3 – Early Trials
|
FGFR2 amplification
|
Breast Cancer
|
FGFR2 amplification
|
Breast Cancer
|
TKI258 Sensitive: C3 – Early Trials
|
TKI258 Sensitive: C3 – Early Trials
|
FGFR2 amplification
|
Breast Cancer
|
FGFR2 amplification
|
Breast Cancer
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
FGFR2 amplification
|
Gastric Cancer
|
FGFR2 amplification
|
Gastric Cancer
|
FGFR inhibitor Sensitive: C3 – Early Trials
|
FGFR inhibitor Sensitive: C3 – Early Trials
|
FGFR2 amplification
|
Breast Cancer
|
FGFR2 amplification
|
Breast Cancer
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FGFR2 amplification
|
Gastric Adenocarcinoma
|
FGFR2 amplification
|
Gastric Adenocarcinoma
|
TAS 120 Sensitive: D – Preclinical
|
TAS 120 Sensitive: D – Preclinical
|
FGFR2 amplification
|
CRC
|
FGFR2 amplification
|
CRC
|
eFT226 Sensitive: D – Preclinical
|
eFT226 Sensitive: D – Preclinical
|
FGFR2 amplification
|
Gastric Cancer
|
FGFR2 amplification
|
Gastric Cancer
|
erdafitinib Sensitive: D – Preclinical
|
erdafitinib Sensitive: D – Preclinical
|
FGFR2 amplification
|
CRC
|
FGFR2 amplification
|
CRC
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FGFR2 amplification
|
NSCLC
|
FGFR2 amplification
|
NSCLC
|
eFT226 Sensitive: D – Preclinical
|
eFT226 Sensitive: D – Preclinical
|
FGFR2 amplification
|
Gastric Cancer
|
FGFR2 amplification
|
Gastric Cancer
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FGFR2 amplification
|
Breast Cancer
|
FGFR2 amplification
|
Breast Cancer
|
eFT226 Sensitive: D – Preclinical
|
eFT226 Sensitive: D – Preclinical
|
FGFR2 amplification
|
Gastric Adenocarcinoma
|
FGFR2 amplification
|
Gastric Adenocarcinoma
|
nintedanib Sensitive: D – Preclinical
|
nintedanib Sensitive: D – Preclinical
|
